Advances in the treatment of atherosclerosis with ligand‐modified nanocarriers
Xiujiao Deng,
Jinghao Wang,
Shanshan Yu,
Suiyi Tan,
Tingting Yu,
Qiaxin Xu,
Nenghua Chen,
Siqi Zhang,
Ming‐Rong Zhang,
Kuan Hu,
Zeyu Xiao
Affiliations
Xiujiao Deng
Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China
Jinghao Wang
Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China
Shanshan Yu
Department of Pharmacy Zhujiang Hospital Southern Medical University Guangzhou China
Suiyi Tan
Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences Southern Medical University Guangzhou China
Tingting Yu
Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China
Qiaxin Xu
Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China
Nenghua Chen
Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China
Siqi Zhang
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Ming‐Rong Zhang
Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical, Science National Institutes for Quantum Science and Technology Chiba Japan
Kuan Hu
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Zeyu Xiao
The Guangzhou Key Laboratory of Basic and Translational Research on Chronic Diseases Jinan University Guangzhou China
Abstract Atherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well‐being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface‐modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over‐expressed in atherosclerotic conditions. This paper reviews recent research (2018–present) advances in various ligand‐modified nanoparticle systems targeting atherosclerosis by specifically targeting signature molecules in the hope of precise treatment at the molecular level and concludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis.
